Zongertinib for treating HER2-mutated unresectable or metastatic non-small-cell lung cancer [ID6573]

  • Awaiting development
  • GID-TA11755
  • Expected publication date: TBC
To appraise the clinical and cost effectiveness of Zongertinib within its marketing authorisation for treating non-small-cell lung cancer